Elicio Therapeutics, Inc. (ELTX)
- Previous Close
9.22 - Open
9.29 - Bid 9.05 x 100
- Ask 9.40 x 100
- Day's Range
9.12 - 9.39 - 52 Week Range
2.96 - 24.39 - Volume
24,580 - Avg. Volume
58,991 - Market Cap (intraday)
94.544M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-6.96 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer, infectious, and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers that is in Phase II clinical trial. It is also developing ELI-004, an AMP-modified CpG adjuvant and a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers. The company is headquartered in Boston, Massachusetts.
elicio.comRecent News: ELTX
Performance Overview: ELTX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELTX
Valuation Measures
Market Cap
94.54M
Enterprise Value
88.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.69
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-89.70%
Return on Equity (ttm)
-346.95%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-35.2M
Diluted EPS (ttm)
-6.96
Balance Sheet and Cash Flow
Total Cash (mrq)
12.89M
Total Debt/Equity (mrq)
60.82%
Levered Free Cash Flow (ttm)
-16.93M